Cencora (NYSE:COR) Issues FY 2025 Earnings Guidance

Cencora (NYSE:COR - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 15.700-15.950 for the period, compared to the consensus estimate of 15.450. The company issued revenue guidance of -, compared to the consensus revenue estimate of $323.6 billion.

Analyst Ratings Changes

Several brokerages have recently issued reports on COR. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. UBS Group upped their price objective on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, Morgan Stanley set a $288.00 price objective on shares of Cencora in a report on Tuesday, April 15th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Cencora presently has an average rating of "Moderate Buy" and an average target price of $301.18.

Cencora Stock Down 0.2 %

Shares of NYSE:COR traded down $0.65 during midday trading on Friday, hitting $283.12. The stock had a trading volume of 2,786,039 shares, compared to its average volume of 1,524,037. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The business's 50-day simple moving average is $276.48 and its 200-day simple moving average is $253.31. Cencora has a 12 month low of $214.77 and a 12 month high of $309.35. The company has a market cap of $54.90 billion, a P/E ratio of 40.27, a PEG ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Cencora's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $3.80 EPS. On average, sell-side analysts forecast that Cencora will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be paid a $0.55 dividend. The ex-dividend date is Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.78%. Cencora's dividend payout ratio is 31.29%.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 4,970 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the sale, the chief executive officer now owns 51,070 shares in the company, valued at $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 50,223 shares of company stock worth $13,580,967. 10.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.